Nycomed Imaging as

Axon Biochemicals B.v.

Nycomed Innovation Ab

Hakan Wikstrom

Klaes Golman

Lars-Goran Wistrand

Sven Goran Andersson

Arne Berg

Harald Dugstad

Torsten Almen

Unni Nordby Wiggen

Durk Dijkstra

Tomas Klingstedt

Frode Rise

Rune Fossheim

Ulrik Jurva

Thomas Cremers

Per Erik Andren

Ib Luenbach

Sandrine Marchais

Oyvind Antonsen

New aporphine derivatives are disclosed which have formula (I) and the physiologically acceptable salts thereof. Said derivatives may be used for the treatment of Parkinson's disease, hemicrania, restless legs syndrome (RLS), sexual dysfunction in men and women, hyperprolactemia and psychotic disorders, and/or evaluation of Parkinson's disease. Processes for the preparation of such derivatives are also disclosed.

Aporphine esters and their use in therapy

The invention provides low viscosity iodinated aryl compounds, useful as X-ray contrast agents, of formula C,R,wherein three non-adjacent R groups are iodine and the remaining R groups are non-ionic, hydrophilic moieties, said compound being water soluble at 20&deg; C. to a concentration of at least 350 mgl/ml and which in aqueous solution at 20&deg; C. at a concentration of 350 mgl/ml has a viscosity no greater than 13.8 mPas.

Iodinated x-ray contrast media

The invention provides low viscosity iodinated aryl compounds, useful as X-ray contrast agents, of formula I ##STR1## (wherein n is 0 or 1, and where n is 1 each C.sub.6 R.sub.5 moeity may be the same or different; each group R is a hydrogen atom, an iodine atom or a hydrophilic moiety M or M.sub.1, two or three non-adjacent R groups in each C.sub.6 R.sub.5 moiety being iodine and at least one, and preferably two or three, R groups in each C.sub.6 R.sub.5 moiety being M or M.sub.1 moieties; X denotes a bond or a group providing a 1 to 7 atom chain linking two C.sub.6 R.sub.5 moieties or, where n is 0, X denotes a group R; each M independently is a non-ionic hydrophilic moiety; and each M.sub.1 independently represents a C.sub.1-4 alkyl group substituted by at least one hydroxyl group and optionally linked to the phenyl ring via a carbonyl, sulphone or sulphoxide group, at least one R group being an M.sub.1 moiety; with the proviso that where n is zero either at least one M.sub.1 group other than a hydroxymethyl or 1,2-dihydroxyethyl group is present or then if one hydroxymethyl or 1,2-dihydroxyethyl M.sub.1 group is present at least one nitrogen-attached or hydroxylated-C.sub.3-4 alkyl moiety-containing M group is also present) and isomers thereof.

Contrast media

The present invention relates to the use of persistent free radicals, in particular persistent free radicals having a carbon-based .pi.-bonded electronic system available for delocalization of the unpaired electrons as image enhancing agents in magnetic resonance imaging (MRI), in particular electron spin resonance enhanced magnetic resonance imaging (ESREMRI). The invention also relates to contrast media containing such radicals and to the use of such radicals and their non-radical precursors in the manufacture of MRI and ESREMRI contrast media.

Use of persistent free-radicals in magnetic resonance imaging

Use of persistent heterocyclic free-radicals in magnetic resonance

Growing community of inventors

Groningen, Netherlands

Hakan Wikstrom